The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Autolus Therapeutics plc ADR (NASDAQ: AUTL) closed at $1.82 up 1.68% from its previous closing price of $1.79. In other words, the price has increased by $1.68 from its previous closing price. On the day, 1.15 million shares were traded.
Ratios:
For a deeper understanding of Autolus Therapeutics plc ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.64 and its Current Ratio is at 13.64. In the meantime, Its Debt-to-Equity ratio is 0.63 whereas as Long-Term Debt/Eq ratio is at 0.62.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on November 18, 2024, Upgraded its rating to Buy and sets its target price to $7.60 from $7 previously.
On November 15, 2024, Redburn Atlantic Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $13.
On November 09, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $10.Deutsche Bank initiated its Buy rating on November 09, 2023, with a $10 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 16 ’24 when Martin Pule bought 698,741 shares for $4.23 per share.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 48.00 while its Price-to-Book (P/B) ratio in mrq is 1.02.
Stock Price History:
Over the past 52 weeks, AUTL has reached a high of $6.62, while it has fallen to a 52-week low of $1.79. The 50-Day Moving Average of the stock is -17.91%, while the 200-Day Moving Average is calculated to be -47.42%.
Shares Statistics:
A total of 266.12M shares are outstanding, with a floating share count of 240.31M. Insiders hold about 9.70% of the company’s shares, while institutions hold 53.78% stake in the company.
Earnings Estimates
The market rating of Autolus Therapeutics plc ADR (AUTL) is currently shaped by the ongoing analysis conducted by 5.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.24 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$0.67 and -$1.09 for the fiscal current year, implying an average EPS of -$0.91. EPS for the following year is -$0.91, with 7.0 analysts recommending between -$0.71 and -$1.19.
Revenue Estimates
A total of 8 analysts have provided revenue estimates for AUTL’s current fiscal year. The highest revenue estimate was $50M, while the lowest revenue estimate was $10.09M, resulting in an average revenue estimate of $17.33M. In the same quarter a year ago, actual revenue was $1.7MBased on 8 analysts’ estimates, the company’s revenue will be $35.96M in the next fiscal year. The high estimate is $61.8M and the low estimate is $18.34M.
